Olaparib/Olaparib official instructions: indications, usage, dosage and precautions

Olaparib/Olaparib Chinese trade name "Lipuzhuo" is a polyadenosine diphosphate-ribose polymerase (PARP) inhibitor jointly developed by AstraZeneca and Merck. It was originally developed to solve the treatment problem of solid tumors with homologous recombination repair deficiency (HRD). According to the official instructions, olaparib has been approved for targeted therapy in multiple tumor types, especially for patients with BRCA mutations. Treatment selection is highly precise and personalized.

In the field of breast cancer, olaparib is approved for the treatment of patients with HER2-negative metastatic breast cancer carrying germlineBRCA mutations (gBRCAm), especially those who have received chemotherapy in the past and are sensitive to platinum-containing drugs. It is particularly widely used in ovarian cancer and is especially suitable for maintenance treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. It is one of the important strategies for long-term disease control in such patients. In addition, olaparib is also approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with HRR (homologous recombination repair) gene mutations, showing a significant delay in disease progression compared with traditional hormone therapy. It is worth noting that olaparib is also the first oral targeted drug approved in the world to treat BRCA-mutated metastatic pancreatic cancer, providing new hope for this tumor with extremely poor prognosis.

In terms of usage and dosage, the official recommended dose is oral administration300 mg twice a day, once in the morning and once in the evening. It is recommended to take it on an empty stomach or with a low-fat diet until the disease progresses or unacceptable adverse reactions occur. During clinical use, if the patient experiences grade ≥3 adverse reactions (such as nausea, vomiting, anemia, fatigue, thrombocytopenia, etc.), the doctor may adjust the dose according to the specific situation. The common dose is adjusted to 250 mg or 200 mg twice a day to ensure the tolerability of the treatment. Special attention should be paid to the fact that olaparib has a certain risk of bone marrow suppression. Long-term use requires regular monitoring of blood routine and liver and kidney function, and avoid the combined use of strong CYP3A inhibitors or inducers to avoid significant interference with drug metabolism.

In terms of safety, the most common adverse reactions of olaparib include nausea, fatigue, decreased appetite, diarrhea, and decreased hemoglobin. Some patients may experience increased transaminases or creatinine. Although most adverse reactions are grade 1-2, it is still recommended to monitor closely during medication and reasonably manage toxic reactions under the guidance of a doctor. In addition, as a DNA repair inhibitor, the potential risks of long-term use of olaparib have also received close attention. A few patients have reported the rare occurrence of acute myeloid leukemia or myelodysplastic syndrome, so it is necessary to remain vigilant during drug use.

To sum up, olaparib, as a representative drug ofPARP inhibitors, not only shows excellent efficacy in multiple solid tumors, but also provides a new direction for precision treatment and maintenance treatment strategies. As clinical trial data continues to accumulate, its indications are expected to be further expanded to help more patients achieve longer progression-free survival. Patients should judge whether they are suitable to use this drug under the guidance of a professional doctor combined with genetic testing results to ensure maximum efficacy and minimize risks.

Reference materials:https://www.lynparza.com/